238 related articles for article (PubMed ID: 25355370)
1. Evaluation of levodopa and carbidopa antioxidant activity in normal human lymphocytes in vitro: implication for oxidative stress in Parkinson's disease.
Colamartino M; Santoro M; Duranti G; Sabatini S; Ceci R; Testa A; Padua L; Cozzi R
Neurotox Res; 2015 Feb; 27(2):106-17. PubMed ID: 25355370
[TBL] [Abstract][Full Text] [Related]
2. A multi-biomarker analysis of the antioxidant efficacy of Parkinson's disease therapy.
Colamartino M; Duranti G; Ceci R; Sabatini S; Testa A; Cozzi R
Toxicol In Vitro; 2018 Mar; 47():1-7. PubMed ID: 29080800
[TBL] [Abstract][Full Text] [Related]
3. Protective effects of L-dopa and carbidopa combined treatments on human catecholaminergic cells.
Colamartino M; Padua L; Meneghini C; Leone S; Cornetta T; Testa A; Cozzi R
DNA Cell Biol; 2012 Nov; 31(11):1572-9. PubMed ID: 23020119
[TBL] [Abstract][Full Text] [Related]
4. Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys.
Lyras L; Zeng BY; McKenzie G; Pearce RK; Halliwell B; Jenner P
J Neural Transm (Vienna); 2002; 109(1):53-67. PubMed ID: 11793162
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson's disease.
Müller T
Expert Opin Drug Metab Toxicol; 2020 May; 16(5):403-414. PubMed ID: 32238065
[No Abstract] [Full Text] [Related]
6. Antioxidant potential of melatonin enhances the response to L-dopa in 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine-parkinsonian mice.
Zaitone SA; Hammad LN; Farag NE
Pharmacol Rep; 2013; 65(5):1213-26. PubMed ID: 24399717
[TBL] [Abstract][Full Text] [Related]
7. Carbidopa-based modulation of the functional effect of the AAV2-hAADC gene therapy in 6-OHDA lesioned rats.
Ciesielska A; Sharma N; Beyer J; Forsayeth J; Bankiewicz K
PLoS One; 2015; 10(4):e0122708. PubMed ID: 25860990
[TBL] [Abstract][Full Text] [Related]
8. Neurochemical, neurobehavioral and histochemical effects of therapeutic dose of l-dopa on striatal neurons in rats: Protective effect of virgin coconut oil.
Shehata AM; Ahmed-Farid OA; Rizk HA; Saber SM; Lashin FM; Re L
Biomed Pharmacother; 2020 Oct; 130():110473. PubMed ID: 32707436
[TBL] [Abstract][Full Text] [Related]
9. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Hossain MA; Weiner N
J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
11. Continuous versus intermittent oral administration of levodopa in Parkinson's disease patients with motor fluctuations: A pharmacokinetics, safety, and efficacy study.
Warren Olanow C; Torti M; Kieburtz K; Leinonen M; Vacca L; Grassini P; Heller A; Heller E; Stocchi F
Mov Disord; 2019 Mar; 34(3):425-429. PubMed ID: 30653246
[TBL] [Abstract][Full Text] [Related]
12. L-dopa-carbidopa: combined therapy for the treatment of Parkinson's disease.
Celesia GG; Wanamaker WM
Dis Nerv Syst; 1976 Mar; 37(3):123-5. PubMed ID: 1253661
[TBL] [Abstract][Full Text] [Related]
13. The Design and Evaluation of an l-Dopa-Lazabemide Prodrug for the Treatment of Parkinson's Disease.
Hoon M; Petzer JP; Viljoen F; Petzer A
Molecules; 2017 Nov; 22(12):. PubMed ID: 29186917
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological evaluation of vanillic acid in rotenone-induced Parkinson's disease rat model.
Sharma N; Khurana N; Muthuraman A; Utreja P
Eur J Pharmacol; 2021 Jul; 903():174112. PubMed ID: 33901458
[TBL] [Abstract][Full Text] [Related]
15. DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons.
Atlas D
CNS Neurosci Ther; 2016 Jun; 22(6):461-7. PubMed ID: 26861609
[TBL] [Abstract][Full Text] [Related]
16. In vivo protective effect of Uridine, a pyrimidine nucleoside, on genotoxicity induced by Levodopa/Carbidopa in mice.
Orenlili Yaylagul E; Cansev M; Celikler Kasimogullari S
Food Chem Toxicol; 2015 Aug; 82():36-41. PubMed ID: 25976300
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of 6-11C-Methyl-m-Tyrosine as a PET Probe for Presynaptic Dopaminergic Activity: A Comparison PET Study with β-11C-l-DOPA and 18F-FDOPA in Parkinson Disease Monkeys.
Kanazawa M; Ohba H; Harada N; Kakiuchi T; Muramatsu S; Tsukada H
J Nucl Med; 2016 Feb; 57(2):303-8. PubMed ID: 26564319
[TBL] [Abstract][Full Text] [Related]
18. Increased dopamine content in lymphocytes from high-dose L-Dopa-treated Parkinson's disease patients.
Rajda C; Dibó G; Vécsei L; Bergquist J
Neuroimmunomodulation; 2005; 12(2):81-4. PubMed ID: 15785109
[TBL] [Abstract][Full Text] [Related]
19. Protective effect of two essential oils isolated from Rosa damascena Mill. and Lavandula angustifolia Mill, and two classic antioxidants against L-dopa oxidative toxicity induced in healthy mice.
Nikolova G; Karamalakova Y; Kovacheva N; Stanev S; Zheleva A; Gadjeva V
Regul Toxicol Pharmacol; 2016 Nov; 81():1-7. PubMed ID: 27381452
[TBL] [Abstract][Full Text] [Related]
20. The combination of lithium and l-Dopa/Carbidopa reduces MPTP-induced abnormal involuntary movements (AIMs) via calpain-1 inhibition in a mouse model: Relevance for Parkinson׳s disease therapy.
Lazzara CA; Riley RR; Rane A; Andersen JK; Kim YH
Brain Res; 2015 Oct; 1622():127-36. PubMed ID: 26119916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
